Last reviewed · How we verify
Premarin vaginal estrogen cream
Premarin vaginal cream delivers conjugated estrogens directly to vaginal tissue to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital symptoms.
Premarin vaginal cream delivers conjugated estrogens directly to vaginal tissue to restore estrogen levels and relieve symptoms of vaginal atrophy and menopausal urogenital symptoms. Used for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.
At a glance
| Generic name | Premarin vaginal estrogen cream |
|---|---|
| Also known as | Conjugated estrogens vaginal cream |
| Sponsor | Medstar Health Research Institute |
| Drug class | Estrogen replacement therapy (topical) |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Menopause |
| Phase | FDA-approved |
Mechanism of action
The cream contains conjugated estrogens (a mixture of estrone and equilin sulfates derived from pregnant mare urine) that are absorbed through the vaginal epithelium. These estrogens bind to estrogen receptors in vaginal and urethral tissues, restoring tissue elasticity, moisture, and blood flow. This reverses the atrophic changes caused by estrogen deficiency in menopause.
Approved indications
- Vaginal atrophy and urogenital symptoms associated with menopause
- Atrophic vaginitis
Common side effects
- Vaginal irritation or discharge
- Breast tenderness
- Headache
- Abdominal pain or bloating
Key clinical trials
- Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery (PHASE3)
- Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity (PHASE4)
- Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder (PHASE4)
- Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse (NA)
- Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy (PHASE4)
- Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection (NA)
- Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen (PHASE4)
- Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Premarin vaginal estrogen cream CI brief — competitive landscape report
- Premarin vaginal estrogen cream updates RSS · CI watch RSS
- Medstar Health Research Institute portfolio CI